Preclinical Rationale for PI3K/Akt/mTOR Pathway Inhibitors as Therapy for Epidermal Growth Factor Receptor Inhibitor-Resistant Non–Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

Preclinical Rationale for PI3K/Akt/mTOR Pathway Inhibitors as Therapy for Epidermal Growth Factor Receptor Inhibitor-Resistant Non–Small-Cell Lung Cancer

Published:2013-07 Issue:4 Volume:14 Page:322-332
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Gadgeel Shirish M.,Wozniak Antoinette

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference90 articles.

1. Epidermal growth factor receptors in non-small cell lung cancer;Veale;Br J Cancer,1987

2. ERBB receptors and cancer: the complexity of targeted inhibitors;Hynes;Nat Rev Cancer,2005

3. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer;Pao;Nat Rev Cancer,2010

4. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer;Miller;J Clin Oncol,2004

5. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial) [corrected];Fukuoka;J Clin Oncol,2003

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unraveling the chemotherapeutic potential of taxifolin ruthenium-p-cymene complex in breast carcinoma: Insights into AhR signaling pathway in vitro and in vivo;Translational Oncology;2024-11

2. Design, synthesis and bioevaluation of dual EGFR-PI3Kα inhibitors for potential treatment of NSCLC;Bioorganic Chemistry;2024-10

3. Combined computational and synthetic strategies for the development of potent pyrazolo-pyridine derivatives as anticancer agents;Journal of Molecular Structure;2024-09

4. PABPC1 silencing inhibits pancreatic cancer cell proliferation and EMT, and induces apoptosis via PI3K/AKT pathway;Cytotechnology;2024-04-22

5. Clinical advances in EGFR-TKI combination therapy for EGFR-mutated NSCLC: a narrative review;Translational Cancer Research;2023-12